Patent application number | Description | Published |
20080227114 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION - The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered. | 09-18-2008 |
20090253694 | Fused hetrocyclic compounds - This invention provides fused heterocyclic compounds, pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders. | 10-08-2009 |
20100120722 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS - This invention relates to pyrimidine compounds of formula (I), formula (I′), and formula (I″): | 05-13-2010 |
20100173413 | PYRIDINE COMPOUNDS - This invention features compounds of formula (I): | 07-08-2010 |
20110098267 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS - The invention relates to a topical composition and a method for treating psoriasis. The topical composition comprises one or more compound that inhibits the production of IL-12 and IL-23. | 04-28-2011 |
20110288081 | PYRIMIDINE COMPOUNDS AND USES THEREOF - This invention features pyrimidine compounds of formula (I): | 11-24-2011 |
20120208203 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION - The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered. | 08-16-2012 |
20130150440 | USE OF BIS [THIOHYDRAZIDE AMIDE] COMPOUNDS SUCH AS ELESCLOMOL FOR TREATING CANCERS - Improved cancer treatments with bis[thiohydrazide amide] compounds such as elesclomol, in particular for identifying patient populations that would benefit from such treatments. | 06-13-2013 |